MeSH tree: N06.850.520.830
For patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the addition of palbociclib to maintenance anti-HER2 and endocrine therapies leads to improved ...
Feb 2, 2026
0
1
Patients with advanced lung cancer who received immunochemotherapy before 15:00 (3 p.m.) had a more delayed disease progression than patients receiving treatment later in the day. The findings, published as part of a randomized ...
Feb 2, 2026
0
39
Despite major advances in genetic testing for breast cancer risk prediction, death rates remain disproportionately high among women of African ancestry. This is often due to a combination of factors, including failure of ...
Feb 2, 2026
0
33
Heart specialists at Mayo Clinic today presented new research at the 2026 Society of Thoracic Surgeons Annual Meeting that redo surgery for adults with congenital heart disease (CHD) remains high-risk, and a clinically applicable ...
Jan 31, 2026
0
0
Researchers at Keele University have said that more targeted use of testing for a common molecule could help to improve predictions of cardiovascular disease outcomes in patients at greatest risk.
Jan 29, 2026
0
0
More than 135 million American adults are either living with or at risk for type 2 diabetes (T2D), elevating the need for more evidence-based dietary guidance to help this growing population achieve optimal health and reduce ...
Jan 28, 2026
0
0
Americans born in the 1960s and early 1970s report higher loneliness and depressive symptoms and show poorer memory and physical strength than earlier generations. Such declines are largely absent in peer countries, particularly ...
Jan 26, 2026
2
36
A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight ...
Jan 23, 2026
0
0
For patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), sacituzumab govitecan plus pembrolizumab yields significantly ...
Jan 22, 2026
0
0
Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the immunotherapy nivolumab (Opdivo) instead of the immunotherapy brentuximab vedotin (brand name Adcetris) along ...
Jan 13, 2026
0
0
